Dermata Therapeutics Inc (DRMA) saw a price increase of 6.58% during regular trading, with the stock crossing above the 20-day SMA. This movement comes amid broader market weakness, as the Nasdaq-100 and S&P 500 both declined slightly.
The surge in DRMA's stock price is attributed to the company's announcement of raising $4.1 million by issuing 2.02 million shares at $2.04 each. This financing is aimed at enhancing liquidity for future growth, including consumer research studies and pre-launch activities for a new acne kit. The participation of Dermata's executives in this financing demonstrates their confidence in the company's future prospects, potentially boosting investor trust.
This positive market reaction reflects a strong outlook for Dermata Therapeutics, as the funds raised will support strategic initiatives that could improve product competitiveness and accelerate growth in a challenging market environment.
Wall Street analysts forecast DRMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRMA is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast DRMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRMA is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.520
Low
10.00
Averages
10.00
High
10.00
Current: 2.520
Low
10.00
Averages
10.00
High
10.00
Maxim
Buy
downgrade
$30 -> $10
2025-08-21
Reason
Maxim
Price Target
$30 -> $10
AI Analysis
2025-08-21
downgrade
Buy
Reason
Maxim lowered the firm's price target on Dermata Therapeutics to $10 from $30 and keeps a Buy rating on the shares. The company's Q2 results saw operating expenses below the firm's estimate and GAAP loss per share narrower than its estimate, though Maxim is cutting its price target to reflect the share dilution from an anticipated capital raise, the analyst tells investors in a research note.
Maxim
Anthony Vendetti
Buy
downgrade
$6 -> $3
2025-05-21
Reason
Maxim
Anthony Vendetti
Price Target
$6 -> $3
2025-05-21
downgrade
Buy
Reason
Maxim analyst Anthony Vendetti lowered the firm's price target on Dermata Therapeutics to $3 from $6 and keeps a Buy rating on the shares. The firm notes the company's Q1 operating expenses were below its estimates while also citing its statistically significant positive topline data from STAR-1 study, though its adjusted model reflects Dermata's anticipated capital raise, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DRMA
Unlock Now
About DRMA
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
